Longevity and AI24 Feb 2026 15:24
Dr Ron sated this: “And R42 for AI and Aging investments” on the following interesting post
“Scientific Validation and Technology Acceleration Unlocks the Longevity Frontier. Over the past three decades, aging research has shifted from theoretical to experimentally validated biology: daf-2 mutations doubled C. elegans lifespan (1993) following age-1 mutants (1988); heterochronic parabiosis (2005) showed that a young systemic milieu can rejuvenate aged tissues; rapamycin (2009) extended mouse lifespan via mTOR inhibition; DNA-methylation clocks (2013) enabled quantitative biological-age measurement; and senescent-cell clearance (2011/2016) delayed age-related pathologies and extended median lifespan in normal mice.
Today, evidence spans hundreds of rodent lifespan-extension protocols (212 protocols across 121 studies compiled in RAID, and hundreds of labs worldwide are advancing aging biology.
Advances in biotechnology and artificial intelligence are now converting decades of discovery into investable solutions, though whether these interventions will meaningfully extend human healthspan remains an open, empirical question. New modalities such as gene therapies, antisense oligonucleotides, programmable biologics, and in vivo editing are moving rapidly from research to clinic. On the Al side, platforms are compressing discovery timelines from years to months: AlphaFold 3 now predicts complex biomolecular interactions (proteins, ligands, nucleic acids, ions) with significantly higher accuracy than prior methods. Exscientia (EXAI) designed a drug candidate in ~12 months using its Al platform, a fraction of the industry-standard 4.5 years and has since advanced multiple programs with Sanofi (SNY), with over $600M in potential milestones remaining.
As novel mechanisms continue to surface, like the elastin-NEU1 axis in vascular aging, tRNA fragment-driven aging pathways, and centenarian multi-omics signatures, they broaden the intervention landscape. Digital endpoints and wearable sensors now enable tracking of biological age and decentralized trials in older populations. Platform technologies such as base editing from Beam Therapeutics (BEAM) and Prime Medicine (PRME) enable precise targeting of aging related genes.
With senolytics, epigenetic reprogramming, and metabolic interventions now in human trials, the field is shifting to engineered therapeutics. Multiple Phase 1 and 2 clinical trials have demonstrated safety and preliminary efficacy in age related conditions, validating specific pathways even as the field grapples with which mechanisms will prove most consequential for human aging”
https://www.linkedin.com/posts/michellebkwok_longevity-as-an-investment-vertical-ugcPost-7431748449894633472-f1cI?utm_source=share&utm_medium=member_ios&rcm=ACoAAA2uNNwBoQ-5IwwwBKIC0zEhck3tCZ0MZ_c